Issues related to biopharmaceutical pricing; Issues related to plasma and plasma derived therapies; Issues related to the Preserving Life-saving Access to Specialty Medicines in America Act.
Source-reported fields
Filing overview
- Type
- 3rd Quarter - Termination
- Posted
- Oct 10, 2025
- Income
- $60,000.00
- Expenses
- Not reported
- Registrant
- FORBES-TATE
- Client
- CSL BEHRING
- Filing UUID
- 0f77a8d8-3960-4a6d-a3b3-416397c4252a
- Termination date
- Sep 30, 2025
Literal source text
Lobbying issues and bill citations
Issues related to biopharmaceutical pricing; Issues related to plasma and plasma derived therapies.
Relationship and amount limits
Bill links use only the filing year’s mathematically derived Congress plus the literal measure type and number in the issue description. Unmatched citations remain plain text. Politically.com does not join on names, infer advocacy positions, combine amendments, or calculate totals across filings.